In preclinical models, genetic deletion of VISTA or treatment with anti-VISTA mAb delayed tumor regression by inducing DC maturation, reducing the abundance of adaptive Foxp3+ Tregs, reducing the abundance of MDSCs, and augmenting the effector function and abundance of CTLs (73, 76). Here, FOXP3 is linked to neoplasm.